- Home
- DVAX vs BILI Comparison
DVAX vs BILI Comparison
Compare DVAX & BILI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DVAX | BILI |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 10.8B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DVAX | BILI |
|---|---|---|
| Price | $15.42 | $28.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $26.50 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 4.8M | 1.6M |
| Earning Date | 02-19-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $330,514,000.00 | ★ $4,180,323,637.00 |
| Revenue This Year | $24.63 | $14.70 |
| Revenue Next Year | $15.85 | $9.46 |
| P/E Ratio | ★ N/A | $105.63 |
| Revenue Growth | ★ 26.73 | 16.95 |
| 52 Week Low | $9.20 | $14.47 |
| 52 Week High | $15.49 | $32.50 |
Technical Indicators
Market Signals| Indicator | DVAX | BILI |
|---|---|---|
| Relative Strength Index (RSI) | 88.49 | 69.96 |
| Support Level | $10.78 | $26.79 |
| Resistance Level | $15.45 | $27.56 |
| Average True Range (ATR) | 0.11 | 0.52 |
| MACD | 0.21 | 0.47 |
| Stochastic Oscillator | 98.51 | 95.99 |
Price Performance
Historical ComparisonAbout DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About BILI Bilibili Inc.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing site. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, catering primarily to Gen Z users. Over time, the platform has broadened its content offerings to include a wider range of interests, successfully attracting a more diverse audience beyond the Gen Z demographic.